CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), which target molecules such as programmed death receptor 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), have shown significant benefits in improving overall survival (OS) for patients with advanced NSCLC.